SR Pharma plc announces IND for a 2nd siRNA therapeutic based on its unique proprietary chemistry

20-Mar-2007 - SR Pharma plc announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug application (IND) for a second siRNA therapeutic which is based on the company 's unique proprietary chemistry. The product is AKIi-5, which is being developed by Quark Biotech Inc ...

SR Pharma plc Announces Start of Phase I trial with Novel RNAi Therapeutic RTP-801i in Age- related Macular Degeneration (AMD)

07-Feb-2007 - SR Pharma plc announced that Quark Biotech Inc. has started a Phase I clinical trial with RTP-801i, a small interfering RNA (siRNA) therapeutic product licensed from Atugen AG, a subsidiary of SR Pharma plc. RTP-801i is based on Atugen's proprietary siRNA (AtuRNAi) technology and modifies the ...

SR Pharma Granted Core RNAi Patent by the European Patent Office

08-Jan-2007 - SR Pharma plc announced that the European Patent Office has granted the Company its core RNAi patent EP 03784183.0. This patent covers its novel, stabilised, small interfering RNA (siRNA) molecules with blunt ends and positional modifications. These proprietary siRNA molecules are referred to as ...

SR Pharma plc Announces Encouraging Results for Atu027 RNAi Showing Therapeutic Efficacy in Mouse Models of Pancreatic Cancer

15-Sep-2006 - SR Pharma plc and its operating subsidiary Atugen AG announce that studies at the Charité Hospital, Berlin have demonstrated the therapeutic efficacy of Atu027 RNAi in animal models of pancreatic cancer. The data showed both inhibition of cancer growth and prevention of metastatic spread, ...

ALTANA Pharma and Atugen Renew Target Validation and License Agreement

21-Feb-2005 - Atugen AG announced that it has renewed its non-exclusive Target Validation and License Agreement with ALTANA Pharma AG for another year. The agreement gives Altana the right to have molecular targets validated by Atugen's discovery team, utilizing a number of proprietary knockdown tools and ...

atugen and Aventis to collaborate in identifying siRNA compounds with the potential for therapeutic development

16-Sep-2004 - Berlin. atugen AG announced that it has signed a collaboration agreement with Aventis to identify siRNA compounds with the potential for therapeutic development. It is planned to combine atugen's proprietary siRNA (short-interfering RNA) technology and expertise in gene silencing with Aventis' ...

Peter Buckel Appointed CEO of atugen AG

09-Jun-2004 - Berlin. atugen AG has announced the appointment of Prof Peter Buckel as CEO. This closely follows the strengthening of the board with the appointment of Prof Bernd Wetzel of Boehringer Ingelheim as non-executive director. Peter Buckel brings to atugen his extensive experience in both the ...

atugen and Sankyo Sign Multi-Year Contract Research Agreement

20-May-2004 - Berlin, Germany. atugen AG announced that it has signed a multi-year contract research agreement with Sankyo Co. Ltd, one of Japan's leading pharmaceutical companies. Both companies have already successfully collaborated on a number of proprietary molecular targets that Sankyo has discovered in ...

atugen AG raises EUR 5 million venture funding for siRNA therapeutics program

siRNA therapeutics patent application published

16-Mar-2004 - Berlin. atugen AG, The Gene Silencing Company(TM), announced that it has raised EUR5 million in its third financing round since it was founded in 1998. The new investment will enable atugen to accelerate its work on the development of siRNA therapeutics. This financing round managed by ...